“`html
10/31/2025 – 02:23 AM
Bubendorf, Switzerland – Bachem (SIX: BANB), a leading provider of peptides and oligonucleotides, has announced a strategic leadership transition, setting the stage for continued growth and innovation in the biopharmaceutical sector.
Anne-Kathrin Stoller to become new CEO at Bachem
The Board of Directors has appointed Anne-Kathrin Stoller as the new Chief Executive Officer, effective January 1, 2026. Stoller, currently Head of Bachem Americas and formerly Chief Marketing Officer (CMO), will succeed Thomas Meier, who is departing after a distinguished 30-year tenure with the company, including nearly six years as CEO, to pursue new opportunities.
“Thomas Meier has been instrumental in Bachem’s enduring success, driving capital-efficient and profitable growth while solidifying the company’s reputation as an innovative and reliable partner for the pharmaceutical industry,” stated Kuno Sommer, Chairman of the Board of Directors of Bachem. “We extend our deepest gratitude for his years of dedicated service, leadership, and exceptional contributions to Bachem.”
Sommer further commented, “We are delighted to announce Anne-Kathrin Stoller, a highly experienced and capable leader from within our own organization, as the next CEO. Her exceptional blend of expertise, leadership acumen, and customer-centric approach will be invaluable as she collaborates with her colleagues on the Executive Committee to propel Bachem’s ongoing success.”
Meier reflected on his time at the company, stating, “Bachem is an exceptional organization that has evolved into a global frontrunner in the development and manufacturing of peptides and oligonucleotides. I am grateful for the privilege of contributing to this journey in various capacities over the past three decades. I extend my sincere appreciation to Bachem’s employees, customers, and my colleagues on the Executive Committee and the Board of Directors for their unwavering support and fruitful collaboration.”
Stoller expressed her enthusiasm for the new role, stating, “I am honored to have earned the trust of the Board of Directors and am committed to working closely with the Executive Committee and all Bachem employees to continue our company’s remarkable success story. Under Thomas Meier’s leadership, Bachem has established a clear path for the future. I thank him for his collegial support over the years and all those at Bachem who work tirelessly every day to ensure that we make a significant contribution to human health.”
Stoller joined Bachem in 2006 and has steadily taken on increasing responsibilities. After holding management positions, including Head of Business Development & Sales Europe, Chief Marketing Officer, and member of the Executive Committee, she took on the role of Chief Operating Officer Americas in 2022 and is responsible for the company’s US business. Anne-Kathrin Stoller studied chemistry in Hannover and Cambridge (UK) and holds a doctorate in bioorganic chemistry from the University of Basel. Her deep scientific background, coupled with her business acumen, positions her ideally to lead Bachem in a rapidly evolving market.
Analysis: Strategic Succession Planning Pays Off
Bachem’s appointment of Stoller exemplifies the power of strategic succession planning. By promoting from within, the company not only ensures a seamless transition but also leverages Stoller’s deep understanding of Bachem’s operations, culture, and market dynamics. This internal promotion avoids the disruption and uncertainty often associated with external CEO hires.
Moreover, Stoller’s experience leading Bachem’s US operations is particularly relevant. The United States is a critical market for biopharmaceuticals, and her leadership in the Americas positions her well to drive growth in this key region. Her background in bioorganic chemistry provides a strong foundation for understanding the complex scientific challenges inherent in peptide and oligonucleotide development and manufacturing.
The market for peptides and oligonucleotides is experiencing substantial growth, driven by advancements in drug delivery technologies and the increasing prevalence of chronic diseases. Bachem, with its established expertise and global presence, is well-positioned to capitalize on these trends. Stoller’s leadership is expected to further strengthen Bachem’s competitive advantage and drive innovation in this dynamic sector.
About Bachem
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272707
FAQ
Who will be CEO of Bachem (BCHMY) starting January 1, 2026?
Anne-Kathrin Stoller will become CEO of Bachem effective January 1, 2026.
When did Bachem announce the CEO change for BCHMY?
Bachem announced the appointment on October 31, 2025.
What roles has Anne-Kathrin Stoller held at Bachem before becoming CEO of BCHMY?
Stoller joined Bachem in 2006 and has served as Head of Business Development & Sales Europe, Chief Marketing Officer, and Chief Operating Officer Americas since 2022.
Who is leaving as CEO of Bachem and how long did he serve?
Thomas Meier is leaving after more than 30 years at Bachem and nearly six years as CEO.
What is Anne-Kathrin Stoller’s educational background relevant to BCHMY leadership?
She studied chemistry in Hannover and Cambridge and holds a doctorate in bioorganic chemistry from the University of Basel.
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/11958.html
